Aktienanalyse zu Madrigal Pharmaceuticals Inc (MDGL)MDGLMadrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Madrigal Pharmaceuticals Inc is a good buy right now due to its strong sales growth momentum, with Rezdiffra achieving $364.3 million in Q2 sales, reflecting a 71% year-over-year increase. Additionally, the current price of $533.76 is significantly below the analyst price targets, which range from $605 to $962, indicating substantial upside potential. The main risk is the forward P/E ratio of 666.67, suggesting high expectations that may not be met if growth slows.

3 analysts cover MDGL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 636.22.